BridgeBio Pharma Inc. (NASDAQ:BBIO) is drawing renewed investor attention as the biotech company advances a slate of rare-disease therapies toward potential regulatory filings and commercial launches.

William Blair initiated coverage on the commercial-stage biotech, highlighting the company’s expanding pipeline of treatments targeting rare genetic conditions.

BridgeBio’s Unique Position

Analyst John Boyle wrote, “BridgeBio is in a unique position with an accelerating launch in Attruby, near-term NDA submissions for disease-modifying therapies setting up late-2026/early-2027 launches, and regulatory submission…”

The analyst initiated coverage with an Outperform rating and a fair value of $93.03 per share.

BridgeBio Pharma’s Attruby (acoramidis) is well-positioned for growth in ATTR-CM. The second-generation stabilizer is competing with Alnylam Pharmaceutical Inc.’s (NASDAQ:ALNY) Amvuttra (vutrisiran, a silencer) and Pfizer Inc.’s (NYSE:PFE) Vyndamax (tafamidis, a first-generation stabilizer).

While investors often debate the clinical profiles among ...